Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
British journal of haematology
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome
Immunomodulatory drugs including thalidomide, lenalidomide (LEN) and pomalidomide (POM), are effective for treating multiple myeloma (MM). POM has shown enhanced efficacy with dexamethasone (DEX). Pegylated liposomal doxorubicin (PLD) with bortezomib is US Food and Drug Administration-approved for treating MM. PLD with LEN or thalidomide has shown efficacy for MM patients. LEN with DEX, PLD and bortezomib achieves high response rates. We evaluated the combination of POM with DEX 40 mg and PLD 5 mg/m
Cohen, Alexa; Spektor, Tanya M; Stampleman, Laura; Bessudo, Alberto; Rosen, Peter J; Klein, Leonard M; Woliver, Thomas; Flam, Marshall; Eshaghian, Shahrooz; Nassir, Youram; Maluso, Tina; Swift, Regina A; Vescio, Robert; and Berenson, James R, "Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma." (2018). Journal Articles and Abstracts. 84.